These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 34764951)
1. Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma. Yang Y; Huang H; Li T; Gao Q; Song Y; Wang Z Front Immunol; 2021; 12():728750. PubMed ID: 34764951 [TBL] [Abstract][Full Text] [Related]
2. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma. Soleimani M; Nappi L; Kollmannsberger C Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478 [TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. Ding L; Dong HY; Zhou TR; Wang YH; Yan T; Li JC; Wang ZY; Li J; Liang C Cancer Med; 2021 Sep; 10(18):6384-6401. PubMed ID: 34382349 [TBL] [Abstract][Full Text] [Related]
4. Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib. Lin Z; Xiao S; Qi Y; Guo J; Lu L J Cancer Res Clin Oncol; 2024 May; 150(5):262. PubMed ID: 38762825 [TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma. Spisarová M; Melichar B; Vitásková D; Študentová H Future Oncol; 2021 Jan; 17(3):241-254. PubMed ID: 33016119 [TBL] [Abstract][Full Text] [Related]
6. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830 [TBL] [Abstract][Full Text] [Related]
7. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma. Tang B; Mo J; Yan X; Duan R; Chi Z; Cui C; Si L; Kong Y; Mao L; Li S; Zhou L; Lian B; Wang X; Bai X; Xu H; Li C; Dai J; Guo J; Sheng X Eur J Cancer; 2021 Oct; 156():83-92. PubMed ID: 34425407 [TBL] [Abstract][Full Text] [Related]
8. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. Varkaris A; Xu W; Davis RB; Healy B; McDermott DF Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046 [TBL] [Abstract][Full Text] [Related]
9. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival. Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945 [TBL] [Abstract][Full Text] [Related]
10. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667 [TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Therapy in Renal Cell Carcinoma. Lee CH; Motzer RJ Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies. Adachi Y; Kamiyama H; Ichikawa K; Fukushima S; Ozawa Y; Yamaguchi S; Goda S; Kimura T; Kodama K; Matsuki M; Miyano SW; Yokoi A; Kato Y; Funahashi Y Cancer Res; 2022 Jan; 82(2):292-306. PubMed ID: 34753772 [TBL] [Abstract][Full Text] [Related]
13. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Hayashi H; Nakagawa K Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270 [TBL] [Abstract][Full Text] [Related]